All type of patients: 2 trials - SHIFT - BEAUTIFUL
| ivabradine vs placebo | No demonstrated result suggested Cardiovascular death or hospital admission for CHF by 18% (not demonstrated) suggested heart failure death by 26% (not demonstrated) suggested hospitalisation for cardiovascular causes by 15% (not demonstrated) suggested CV death, MI hospitalization for HF by 18% (not demonstrated) suggested hospitalisation for heart failure by 26% (not demonstrated) | |
| ivabradine 15mg vs placebo | No demonstrated result |
All type of patients: 14 trials - Borer (CL2-009) 5mg - Ruzyllo (CL3-023) 15mg - INITIATIVE (CL3-017, Tardif) 20mg - ASSOCIATE (Tardif) - CL3-018 15mg - CL3-018 10mg - Borer (CL2-009) 10mg - Borer (CL2-009) 20mg - INITIATIVE (CL3-017, Tardif) 15mg - CL3-023 (15mg) - CL3-023 (20mg) - Ruzyllo (CL3-023) 20mg - BEAUTIFUL (angina subgroup) - SIGNIFY
| ivabradine vs amlodipine | No demonstrated result | |
| ivabradine 10mg vs placebo | No demonstrated result | |
| ivabradine 10mg vs placebo on top of amlodipine | No demonstrated result | |
| ivabradine 15mg vs amlodipine | No demonstrated result | |
| ivabradine 15mg vs atenolol | No demonstrated result | |
| ivabradine 15mg vs placebo (on top standard treatment) | No demonstrated result | |
| ivabradine 15mg vs placebo on top of amlodipine | No demonstrated result | |
| ivabradine 15mg vs placebo on top of atenolol | No demonstrated result | |
| ivabradine 20mg vs amlodipine | No demonstrated result | |
| ivabradine 20mg vs atenolol | No demonstrated result | |
| ivabradine 20mg vs placebo | No demonstrated result | |
| ivabradine 5mg vs placebo | No demonstrated result |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
